People: Dean L. Fanelli, Ph.D., Partner

Photo of Dean L. Fanelli, Ph.D., Partner

Dean L. Fanelli, Ph.D.

Partner

Washington, D.C.
Direct: (202) 828-3573
0

Dean L. Fanelli, Ph.D.  is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office.  Dr. Fanelli’s practice focuses on the chemical, pharmaceutical, and biotechnology industries and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings.  Dr. Fanelli also focuses his practice on Paragraph IV litigation strategies, Hatch-Waxman litigation, and biosimilar market assessment and litigation strategy.

Dr. Fanelli’s focus is on pharmaceutical and chemical related technologies including those in the fields of new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as Paragraph IV ANDA analyses and associated Hatch-Waxman Paragraph IV litigation.

Previously, Dr. Fanelli was a Founding Partner and Chair of Fanelli Haag PLLC.  Fanelli Haag joined Seyfarth Shaw LLP in October 2016. Fanelli Haag was a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, and chemical industries.  In 2015, Corporate Counsel ranked Fanelli Haag as a “Most-Favored IP Boutique — One of the Best Firms in IP,” according to a report from BTI Consulting Group.  CorporateINTL Magazine named Fanelli Haag “2016 Biotech Patent Law Firm of the Year” in Washington, D.C. Additionally, Fanelli Haag was named ACQ Global Legal Awards' 2016 “Game Changer of the Year” in Washington, D.C.

Dr. Fanelli has firsthand experience in translating technologies into a successful commercial ventures.  While at Fanelli Haag, Dr. Fanelli was a co-founder of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Fanelli Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.  In addition, Dr. Fanelli has developed various patent portfolios for commercially relevant products including those directed to:  Dificid® (fidaxomicin), which is currently marketed for the treatment of infections related to C. difficile, and Nexterone® (amiodarone HCl), marketed for the treatment and prophylaxis of ventricular fibrillation.  

Prior to founding Fanelli Haag, Dr. Fanelli was in private practice in the Washington D.C. offices of two international law firms, where his work focused primarily on patent prosecution and counseling of clients in the pharmaceutical, chemical, cosmetic and nutritional industries.  Dr. Fanelli also has expertise with medical products, chemical compounds, polymer compositions, food additives and cosmetic compositions. 

Dr. Fanelli gained additional experience in strategic patent management and licensing while working in-house with an international pharmaceutical drug-delivery company and while working in-house with a major consumer product company.

Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society.  He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.

 

Dean L. Fanelli, Ph.D.  is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office.  Dr. Fanelli’s practice focuses on the chemical, pharmaceutical, and biotechnology industries and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings.  Dr. Fanelli also focuses his practice on Paragraph IV litigation strategies, Hatch-Waxman litigation, and biosimilar market assessment and litigation strategy.

Dr. Fanelli’s focus is on pharmaceutical and chemical related technologies including those in the fields of new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as Paragraph IV ANDA analyses and associated Hatch-Waxman Paragraph IV litigation.

Previously, Dr. Fanelli was a Founding Partner and Chair of Fanelli Haag PLLC.  Fanelli Haag joined Seyfarth Shaw LLP in October 2016. Fanelli Haag was a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, and chemical industries.  In 2015, Corporate Counsel ranked Fanelli Haag as a “Most-Favored IP Boutique — One of the Best Firms in IP,” according to a report from BTI Consulting Group.  CorporateINTL Magazine named Fanelli Haag “2016 Biotech Patent Law Firm of the Year” in Washington, D.C. Additionally, Fanelli Haag was named ACQ Global Legal Awards' 2016 “Game Changer of the Year” in Washington, D.C.

Dr. Fanelli has firsthand experience in translating technologies into a successful commercial ventures.  While at Fanelli Haag, Dr. Fanelli was a co-founder of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Fanelli Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.  In addition, Dr. Fanelli has developed various patent portfolios for commercially relevant products including those directed to:  Dificid® (fidaxomicin), which is currently marketed for the treatment of infections related to C. difficile, and Nexterone® (amiodarone HCl), marketed for the treatment and prophylaxis of ventricular fibrillation.  

Prior to founding Fanelli Haag, Dr. Fanelli was in private practice in the Washington D.C. offices of two international law firms, where his work focused primarily on patent prosecution and counseling of clients in the pharmaceutical, chemical, cosmetic and nutritional industries.  Dr. Fanelli also has expertise with medical products, chemical compounds, polymer compositions, food additives and cosmetic compositions. 

Dr. Fanelli gained additional experience in strategic patent management and licensing while working in-house with an international pharmaceutical drug-delivery company and while working in-house with a major consumer product company.

Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society.  He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.

 

Education

  • J.D., The George Washington University Law School

  • Ph.D., Organic Chemistry, Temple University

  • B.S., Chemistry, Villanova University

Admissions

  • District of Columbia
  • New York
  • Registered Patent Attorney, U.S. Patent and Trademark Office

Courts

  • United States Supreme Court

Affiliations

  • American Chemical Society
  • American Bar Association
  • American Intellectual Property Law Association
  • District of Columbia Bar Association
  • New York State Bar Association

Presentations

  • "Protecting Your Trade Secrets in the Pharmaceutical Industry," Webinar, presented by Seyfarth Shaw LLP (June 28, 2017)
  • 7th Global Intellectual Property Convention 2015, New Delhi India (January 2015)
  • 6th Global Intellectual Property Convention 2014, New Delhi India (January 2014)
  • World Intellectual Property Forum 2013, Bangalore, India (January 2013)

Publications

Legal Publications

  • Co-Author, "ANDA Filers Subject to Specific Personal Jurisdiction Based on Future Infliction of Real-World Market Injury," BioLoquitur Life Sciences Blog (April 5, 2016)
  • Co-Author, "Federal Circuit Affirms Holding of Obviousness of Claims Covering Warner Chilcott’s Osteoporosis Drug, Altevia®,”  BioLoquitur Life Sciences Blog (March 29, 2016)
  • Author, "Federal Circuit Determines that Certain PTO Delays May Not Necessitate Patent Term Adjustment,” BioLoquitur Life Sciences Blog (March 1, 2016)
  • Author, "Federal Circuit Confirms Same Inter Partes Review Panel Can Grant Petition and Make Final Determination,” BioLoquitur Life Sciences Blog (January 27, 2016)
  • Co-Author, "Federal Circuit Finds Inter Partes Reviews Constitutional," BioLoquitur Life Sciences Blog (December 8, 2015)
  • Co-Author, "PTO Reports to Congress on Confirmatory Genetic Diagnostic Testing," BioLoquitur Life Sciences Blog, October 26, 2015
  • Co-Author, "Reputational Harm for Failing to Name an Inventor on a Patent Could Give Rise to Article III Standing,” BioLoquitur Life Sciences Blog, October 19, 2015
  • Co Author, "Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB," BioLoquitur Life Sciences Blog (September 28, 2015)
  • Co-Author, "Amgen v. Sandoz: What "Shall" Biosimilar Applicants Do?,"" BioLoquitur Life Sciences Blog (August 24, 2015)
  • Co-Author, "Federal Circuit Deals Blow to Biotech Industry and Diagnostic Method Patents," BioLoquitur Life Sciences Blog (June 15, 2015)
  • Co-Author, “Reverse Settlement Payments in Patent Disputes Come Under Scrutiny Under Both Federal Law and State Antitrust Law,” BioLoquitur Life Sciences Blog (June 1, 2015)
  • Co-Author, “The Future of Biosimilars in Health Care and Litigation,” Law360 (June 24, 2010)
  •  Co-Author, “Time is Money:  Federal Circuit Affirms Wyeth,” IPO Articles and Reports, Pats. Sec., 2010, No. 8
  • Co-Author, “The Future of Biosimilars in Health Care and Litigation,” Law 360 (June 28, 2010) 
  • Co-Author, “A Review of Recent Decisions of the United States Court of Appeals for the Federal Circuit, 2007 Patent Law Decisions of the Federal Circuit,” Volume 57, No. 4, pp. 821-1038 (April 2008)
  • Author, “Claiming Novel Polymorphic Forms of Drug Products,” Journal of the Patent and Trademark Office Society, Volume 88, No. 12, pp. 1053-1067 (December 2006) 

Scientific Publications

  • Co-Author, “Applications of the Sulfinimine-Mediated Asymmetric Strecker Synthesis to the Synthesis of ?-Alkylated-?-Amino Acids,” The Journal of Organic Chemistry (2000)
  • Co-Author, Sulfinimines (Thiooxime S-Oxides): Asymmetric Synthesis of (R)-(+)-β-Phenylalanine From (S)-(+)-N-(Benzylidene)-p-Toluenesulfinamide,” Organic Synthesis (2000)
  • Co-Author, “Asymmetric Synthesis of Sulfinimines (Thiooxime S-Oxides) From p-Toluenesulfinamide and Aldehydes and Ketones,” The Journal of Organic Chemistry (1999)
  • Co-Author, “Sulfinimine Medicated Asymmetric Synthesis of (R)-(4-Methoxy-3,5- dihydroxyphenyl) glycine: The Central Amino Acid of Vancomycin and Related Agents,” The Journal of Organic Chemistry (1998)
  • Co-Author, “Asymmetric Synthesis and Properties of Sulfinimines (Thiooxime S-Oxides),” The Journal of Organic Chemistry (1997)

Accolades

  • Temple University Dissertation Fellowship 1999
  • Temple University Case Fellow 1998
  • Temple University Swern Fellow 1998
  • Villanova Research Fellowship 1993
  • Rohm and Haas Research Fellowship 1992
  • Bryn Mawr College Summer Fellowship 1988